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Background: Sarcopenia, systemic inflammation, and low muscularity significantly
impact the survival of cancer patients. However, few studies have investigated how
sarcopenia and systemic inflammation affect the prognosis of biliary tract cancer with
distant metastasis. In this study, we investigated the association between sarcopenia
with systemic inflammation and prognosis of metastatic biliary tract cancer.
Materials and Methods: Data collected from 353 metastatic biliary tract cancer
patients from 2007 to 2016 were analyzed. To evaluate the skeletal muscle mass,
computed tomography images at the upper level of the third lumbar vertebra (L3) were
used. Sarcopenia was defined using the Japan Society of Hepatology guideline; L3
muscle index <42 cm2/m2 for male and <38 cm2/m2 for female patients. Systemic
inflammation was evaluated using the neutrophil lymphocyte ratio (NLR). Patients with
NLR > 3 were categorized into the inflammatory category. The overall survival (OS)
and progression free survival (PFS) were analyzed. Subgroup analysis was performed
on those who received gemcitabine/cisplatin (GP) chemotherapy and depending on the
presence of sarcopenia and inflammation.
Results: Patients with sarcopenia showed lesser 1-year OS than those without (25.5 vs.
38.2%, p= 0.019). The patients with high NLR (NLR > 3) were associated with a shorter
OS than were those with a low NLR (NLR ≤ 3) (21.0 vs. 52.8%, p < 0.001). Based on
these results, we categorized the patients into three groups; sarcopenia accompanied
by high NLR, no sarcopenia and low NLR, and either sarcopenia or high NLR. The OS
of patients was well-stratified according to this grouping (1-year OS; 18.3 vs. 30.3 vs.
55.8%, p < 0.001). Concordant with OS results, the PFS was well-stratified based on
the presence of either sarcopenia or high NLR (Sarcopenia; 9.5 vs. 19.4%, p < 0.001,
NLR; 10.0 vs. 23.4%, p < 0.001). The PFS was significantly associated with high NLR
and sarcopenia (1-year PFS; 7.8 vs. 13.0 vs. 27.9%, p < 0.001).
Conclusion: Sarcopenia with inflammation was associated with inferior OS and PFS. In
addition, sarcopenia accompanied by inflammation was associated with poor prognosis.
Conservative treatments such as nutritional support, exercise, and pharmacologic
intervention could help metastatic biliary tract cancer patients to overcome sarcopenia
and the inflammatory status.
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INTRODUCTION
Sarcopenia, the loss of skeletal mass and strength, is part of the
normal aging process as well as other health problems such as
liver cirrhosis, renal failure, cognitive problems, and cancer (1, 2).
The importance of sarcopenia in cancer has been increasingly
recognized, as low muscularity is a significant predictor of poor
prognosis in various cancers (3–5).
Studies have shown that low skeletal muscle mass before
surgery was significantly associated with overall survival (OS)
in biliary tract cancer (BTC) patients (6, 7). Only few reports
have reported sarcopenia as a prognostic factor for advanced
BTC. If loss of skeletal muscle mass occurs, the tolerance
to anticancer treatment is reduced, which is associated with
reduced survival (8, 9). However, the mechanism of sarcopenia
in malignancy is not fully defined (10). Available literature
suggests that sarcopenia in patients with malignancy is related to
inflammation as well as older age and poor performance (9, 11).
Low muscularity of patients could lead to inflammation around
the muscle and can contribute to systemic inflammation (12).
Due to limited knowledge on the mechanism of sarcopenia,
the clinical management of sarcopenia is limited and complex
(10, 13, 14). Over the past few decades, our understanding of
sarcopenia has improved, but there is still a lack of a definition
and diagnostic criteria for sarcopenia.
Several studies have demonstrated that systemic inflammation
is related to poor prognosis (15, 16). To evaluate the systemic
inflammatory status, common inflammatory markers such as
neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio
(PLR), and C-reactive protein (CRP) were used. Previous studies
showed that colorectal, small cell lung, and head and neck cancer
patients with high NLR and low skeletal muscle mass have
an inferior OS (17–19). In this study, we investigated whether
sarcopenia accompanied by systemic inflammation affected the
overall survival in advanced BTC patients.
PATIENTS AND METHODS
Patient Population
We retrospectively reviewed the data of advanced BTC patients
from a single institution. Patients with gallbladder cancer,
FIGURE 1 | Computed tomography images of patients with (Left) and without sarcopenia (Right). The two patients had similar body mass indices.
intrahepatic, perihilar, extrahepatic bile duct cancer, and ampulla
of Vater cancer were included in this study, and those with distant
metastasis at initial diagnosis were analyzed.
Totally 353 patients diagnosed metastatic BTC in Gangnam
Severance Hospital from January 2007 to November 2016 met
the inclusion criteria. The diagnosis was made through tissue
biopsy or cytology. The inclusion criteria for this study were as
follows: (1) age over 18 years; (2) diagnosis of BTC via histologic
confirmation; (3) metastatic BTC at diagnosis; and (4) patients
with available medical records.
The exclusion criteria were as follows: (1) patients with
widespread brain or leptomeningeal metastasis; (2) uncontrolled
infections or poor medical conditions; (3) synchronous
malignancies; (4) patients lost at follow-up; and (5) patients
where the tissue area at the third lumbar level could not be
measured or patients without height data. This study was
approved by the institutional review board of the Gangnam
Severance Hospital (3-2019-0257). Informed consent was not
required owing to the retrospective nature of the study.
Measurement of Body Composition and
Definition of Sarcopenia
The previously validated computed tomography (CT)-based
body composition measurement method was used to identify
if a patient had sarcopenia. We selected a single axial slice
at the upper border of third lumbar spine vertebra (L3) level
for measurement. The delineation of skeletal muscle, visceral
fat, and subcutaneous fat tissue was performed using the
MIM Vista software (MIM corp., Version 6.6.14, OH, USA)
based on Hounsfield units (HUs). The threshold of HUs was
applied as follows: Skeletal muscle (−29 to +150 HU); visceral
fat tissue (−150 to −50 HU); and subcutaneous fat tissue
(−190 to −30 HU). The measurements for sarcopenia were
performed by a single radiation oncologist (B. M. Lee). All other
researchers involved in this study were blinded to the outcome
of measurements.
To determine the amount of skeletal muscle, the L3 skeletal
muscle index was used. First, the cross-sectional volume at the
L3 level was divided by the thickness of the axial slice to get the
cross-sectional area. The cross-sectional areas were divided by
the height of the patients to obtain the L3 skeletal muscle index.
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TABLE 1 | Patient characteristics.
Variables No. %







Gall bladder 130 36.80%
Intrahepatic bile duct 112 31.70%
Non-hilar bile duct 43 12.20%






ECOG 0 27 7.70%
ECOG 1 131 37.20%
ECOG 2 141 40.10%
ECOG 3 37 10.50%
ECOG 4 16 4.50%
CA 19-9 (median, IQR) 311.85 (36.65–3262.2)
CA 19-9 normal 85 24.10%
CA 19-9 elevated 267 75.90%
CEA (median, IQR) 4.45 (2.20–24.80)
CEA normal 187 53.10%
CEA elevated 165 46.90%
Albumin
≥3.4 (g/dL) 259 73.40%
<3.4 (g/dL) 94 26.60%
Protein
≥6.9 (g/dL) 186 52.70%
<6.9 (g/dL) 167 47.30%
Cholesterol
<139 (mg/dL) 91 25.80%
≥139 (mg/dL) 262 74.20%
BUN
<23.0 (mg/dL) 304 86.10%
≥23.0 (mg/dL) 49 13.90%
Bilirubin
<1.2 (mg/dL) 192 54.50%
≥1.2 (mg/dL) 160 45.50%
C-reactive protein
<8.0 (mg/L) 100 29.00%




IQR, interquartile range; WD, well-differentiated; MD, moderately differentiated; PD, poorly
differentiated; ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbohydrate
antigen 19-9; CEA, carcinoembryonic antigen; BUN, blood urea nitrogen.






No. % No. %
Age (median, IQR) 71 (62–79) 65 (56–71)
<67 53 33.30% 113 58.20% <0.001
≥67 106 66.70% 81 41.80%
Sex
Male 77 48.40% 126 64.90% 0.002
Female 82 51.60% 68 35.10%
Primary
Gall bladder 56 35.20% 74 38.10% 0.618
Intrahepatic bile duct 53 33.30% 59 30.40%
Non-hilar bile duct 16 10.10% 27 13.90%
Perihilar bile duct 28 17.60% 30 15.50%
Ampullary 6 3.80% 4 2.10%
Pathology
WD/MD 79 69.90% 123 78.30% 0.115
PD 34 30.10% 34 21.70%
Performance status
ECOG 0 7 4.40% 20 10.30% <0.001
ECOG 1 43 27.20% 88 45.40%
ECOG 2 75 47.50% 66 34.00%
ECOG 3 22 13.90% 15 7.70%
ECOG 4 11 7.00% 5 2.60%
CA 19-9 (median, IQR) 373.9 (44.9–3190.0) 241.1 (29.9–3494.7)
CA 19-9 normal 34 21.40% 51 26.40% 0.271
CA 19-9 elevated 125 78.60% 142 73.60%
CEA (median, IQR) 7.30 (2.60–25.00) 3.70 (1.90–24.50)
CEA normal 75 47.20% 112 58.00% 0.042
CEA elevated 84 52.80% 81 42.00%
Albumin
≥3.4 (g/dL) 104 65.40% 155 79.90% 0.002
<3.4 (g/dL) 55 34.60% 39 20.10%
Protein
≥6.9 (g/dL) 74 46.50% 112 57.70% 0.036
<6.9 (g/dL) 85 53.50% 82 42.30%
Cholesterol
<139 (mg/dL) 42 26.40% 49 25.30% 0.805
≥139 (mg/dL) 117 73.60% 145 74.70%
BUN
<23.0 (mg/dL) 134 84.30% 170 87.60% 0.365
≥23.0 (mg/dL) 25 15.70% 24 12.40%
Bilirubin
<1.2 (mg/dL) 85 53.50% 107 55.40% 0.710
≥1.2 (mg/dL) 74 46.50% 86 44.60%
C-reactive protein
<8.0 (mg/L) 43 27.40% 57 30.30% 0.550
≥8.0 (mg/L) 114 72.60% 131 69.70%
Neutrophil lymphocyte ratio
≤3.0 43 27.20% 86 44.60% 0.001
>3.0 115 72.80% 107 55.40%
IQR, interquartile range; WD, well-differentiated; MD, moderately differentiated; PD, poorly
differentiated; ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbohydrate
antigen 19-9; CEA, carcinoembryonic antigen; BUN, blood urea nitrogen.
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According to international consensus, sarcopenia is defined as
an L3 muscle index of <55 and 39 cm2/m2 for male and female
patients, respectively (20). However, the studies contributing to
this consensus were mostly based on the European and American
guidelines (21, 22). As the patients included in this study were of
Asian descent, the Japan Society of Hepatology (JSH) guideline
was used and sarcopenia was defined as L3 muscle index <42
cm2/m2 for male and 38 cm2/m2 for female patients (23).
Figure 1 demonstrates the CT images of patients with sarcopenia
and without sarcopenia.
Indicator of Inflammatory Status
The NLR was used to evaluate the inflammatory status of
patients, and calculated by dividing the neutrophil count by
the lymphocyte count. Every patients underwent the complete
blood count before the administering the chemotherapy and
based on this examination results, we calculated the NLR value.
The optimal cut off values for NLR were different in each study
(24, 25). We adopted the cut off value of NLR that was previously
used for metastatic BTC (25).
Statistical Analysis
The Fisher’s exact test or χ2-test was used to analyze categorical
data. For continuous data, the Mann–Whitney U-test was used
for comparison. OS was defined as the time from the date of
diagnosis to either death due to any cause or to last follow-
up. The progression free survival (PFS) was defined as the
time from the date of diagnosis to date of either disease
progression or death. The survival curves were evaluated using
the Kaplan–Meier method. The univariate and multivariate
analyses were performed using the Cox proportional hazards
model to determine the association between OS, PFS, and the
factors we suggested. The multivariate analysis was conducted
using the variables that were significant predictors of OS and PFS
in the univariate analysis with backward stepwise. The hazard
ratios (HRs) and 95% confidence intervals (CIs) were calculated.
A p < 0.05 was considered statistically significant. The analyses




A total of 353 patients were included with a median follow-up
of 7.77 months [interquartile range (IQR): 3.27–14.70]. Table 1
shows the overall patients’ characteristics. The median age was
67 years (IQR: 58–75), and there were 203 male patients (57.5%).
Of the 353 patients, 158 (44.9%) showed good performance
status with ECOG (Eastern Cooperative Oncology Group) 0 or
1, while 194 (55.1%) had poor performance status (ECOG ≥2).
Histologically, 202 tumors (74.8%) were either well-differentiated
or moderately differentiated.
We divided the patients into two groups according to the
presence of sarcopenia. Table 2 compares the characteristics
between the patients with and without sarcopenia. Sarcopenia
was associated with older age (71 vs. 65-years, p < 0.001)
and female sex (51.6 vs. 35.1%, p = 0.002). The sarcopenia
group had more patients with poor performance status (ECOG
≥2) than the non-sarcopenia group (68.4 vs. 44.3%, p <
0.001). There were significant differences in the blood chemistry
profile between the two groups. There were more patients with
hypoalbuminemia and hypoproteinemia in the sarcopenia group
(hypoalbuminemia: 34.6 vs. 20.1%, p = 0.002; hypoproteinemia:
53.5 vs. 42.3%, p= 0.036). There were more patients with NLR>
3 in the sarcopenia group (72.8 vs. 55.4%, p < 0.001).
Analysis of Overall Survival and Prognostic
Factors
ThemedianOS of all patients in this study was 7.77months (IQR;
3.27–14.70). The median OS was 5.23 and 8.90 months in the
sarcopenia and non-sarcopenia groups, respectively (p = 0.057).
The 1-year OS was significantly different between those with and
without sarcopenia (25.5 vs. 38.2%, p = 0.020; Figure 2). As the
mechanism of sarcopenia in cancer patients was known to be
associated to cancer-related inflammation, we assessed the effect
of systemic inflammation on survival using NLR. The 1-year OS
for patients with NLR> 3 was 21.0% whereas for those with NLR
≤ 3 was 52.8% (p < 0.001; Figure 3).
Based on this result, we analyzed survival depending on
sarcopenia and inflammatory status. The patients were stratified
into three groups according to sarcopenia and NLR as follows:
patients with no sarcopenia and NLR ≤ 3, patients with
sarcopenia and NLR > 3, and patients with either sarcopenia or
NLR > 3. The survival of patients with sarcopenia and NLR > 3
was significantly poorer than those without sarcopenia and NLR
≤ 3. The 1-year OS for patients showing NLR ≤ 3 and without
sarcopenia was 55.8%, while the 1-year OS for the group with
NLR > 3 and sarcopenia and either sarcopenia or NLR > 3 was
18.3 and 30.3%, respectively (p < 0.001; Figure 4).
The results of univariate and multivariate analysis are
summarized in Table 3. In univariate analysis, 12 variables were
factors associated with survival. The 12 variables were as follows;
sex, pathology, ECOG, carbohydrate antigen 19-9 (CA 19-
9), CRP, albumin, protein, cholesterol, BUN, NLR, Sarcopenia,
group stratification based on sarcopenia and NLR. Among these
12 variables, we excluded the NLR and sarcopenia since there
were significant correlation between group stratification and both
sarcopenia status and NLR. Totally, 10 independent variables
were included in the multivariate logistic regression analysis
using backward stepwise (17). In the multivariate analysis, group
with sarcopenia and high NLR (p = 0.004) were significantly
associated with poor OS along with male patients (p = 0.010),
patients with higher CA 19-9 (p = 0.032), and those with poor
ECOG status (p < 0.001).
Progression Free Survival and Prognostic
Factors
The PFS was analyzed according to sarcopenia and inflammatory
status. As shown in Figure 5, sarcopenia was associated with
inferior PFS (1-year PFS; 9.5 vs. 19.4%, p < 0.009). In addition,
patients with NLR > 3 showed inferior PFS compared to those
with NLR ≤ 3 (1-year PFS; 10.0 vs. 23.4%, p < 0.001; Figure 6).
Patients with sarcopenia and high NLR demonstrated lesser PFS
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FIGURE 2 | Overall survival of patients with and without sarcopenia.
FIGURE 3 | Overall survival of patients with high and low NLR.
than the other two groups (1-year PFS; 7.8 vs. 13.0 vs. 27.9%, p <
0.001; Figure 7).
In the univariate analysis, NLR, sarcopenia, and group
depending on NLR status and sarcopenia were significantly
associated with PFS. Sarcopenia with NLR > 3 was a significant
predictor of poor PFS. Along with high NLR and sarcopenia,
poorly differentiated carcinoma (p = 0.017), poor performance
(p < 0.001), and high CA 19-9 (p = 0.011) were significant
predictors of poor PFS (Table 4).
The Subgroup Analysis of OS and PFS for
Patients Who Received GP Chemotherapy
A subgroup analysis was performed for patients who had
received gemcitabine/cisplatin (GP) based chemotherapy.
Of the 353 patients, 132 received GP chemotherapy. The
median follow-up period was 10.67 months (IQR; 5.97–
18.48). The OS and PFS rates for patients who received GP
chemotherapy were evaluated depending on sarcopenia and
inflammatory status.
The OS and PFS were not significantly different between
the sarcopenia and non-sarcopenia groups among patients who
received GP chemotherapy. The 1-year OS for sarcopenia and
non-sarcopenia patients were 42.6 and 50.7%, respectively
(p = 0.844; Supplementary Figure 1). The 1-year PFS
was 12.7 and 28.0% for sarcopenia and non-sarcopenia
patients, respectively (p = 0.123; Supplementary Figure 2).
The patients with NLR > 3 had significantly poorer OS
and PFS than patients with NLR ≤ 3 (1-year OS; 63.0 vs.
36.5%, p = 0.003, 1-year PFS; 27.3 vs. 17.6%, p = 0.008;
Supplementary Figures 3, 4).
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FIGURE 4 | Overall survival of patients depending on sarcopenia and NLR status.
The results of univariate and multivariate analysis in OS
among patients who received GP chemotherapy are shown
in Supplementary Table 1. The OS was not affected by the
sarcopenia (p = 0.844) but was affected by the high NLR
(p = 0.003) in the univariate analysis. The multivariate
analysis also showed the relevance of OS and high NLR (p
= 0.019). The results of univariate and multivariate analysis
of PFS are shown in Supplementary Table 2. Sarcopenia was
not associated with PFS but the inflammation status was
significantly associated with PFS (p = 0.003). The NLR
status remained significant for predicting PFS in multivariate
analysis (p= 0.019).
Analysis of Subcutaneous Adipose Tissue
Index and Visceral Adipose Tissue Index
To evaluate the prognostic significance depending on
subcutaneous adipose tissue index (SATI) and visceral adipose
tissue index (VATI), we compared the OS according to high
and low SATI and VATI. The cut off value for VATI and
SATI were determined using median values. The VATI cut
off values were 29.5 and 28.5 cm2/m2 for female and male
patients, respectively. The cut off values of SATI were 56.5 and
26.5 cm2/m2 for female and male patients, respectively. More
sarcopenia than non-sarcopenia patients had either low VATI
or low SATI (VATI; 57.2 vs. 41.8%, p = 0.004, SATI; 61.0 vs.
36.6%, p < 0.001).
We compared the OS of patients depending on VATI and
SATI. There was no difference in OS between patients with high
VATI and low VATI (1-year OS: 34.6 vs. 30.2%, p = 0.860).
In addition, concordant with VATI results, SATI was not a
significant factor for OS. The 1-year OS for high and low SATI
was 35.0 and 29.7% (p = 0.155), respectively. Altogether, the
adipose index was not associated with OS in metastatic BTC.
DISCUSSION
In this study, we demonstrated that sarcopenia was associated
with poor OS and PFS in BTC patients with distant metastasis at
diagnosis. Furthermore, highNLR, which indicates inflammatory
status, was also associated with reduced OS and PFS. Based on
these two results, we stratified the patients into three groups. The
patients with both sarcopenia and high NLR showed the poorest
OS and PFS compared to those without sarcopenia and low NLR
(NLR ≤ 3), and those with either sarcopenia or high NLR.
There is increasing evidence that the loss of muscle may
affect the prognosis of cancer (4, 5). As patients with malignancy
are generally more vulnerable to degenerative conditions, the
decrease in muscle mass, and dysfunction could be easily
identified. In particular, patients with malignancy that have
progressed to the unresectable or metastatic stage are more
likely to be affected by sarcopenia (26). The relevance between
sarcopenia and poor prognosis had been shown in breast (5), lung
(3), esophageal (27), hepatocellular (28), and colon cancers (29).
Yoon et al. used two ways to evaluate the sarcopenia status
of BTC patients; skeletal muscle attenuation; and index. They
also suggested that those with low skeletal muscle attenuation
had negative influence on survival when compared to those that
underwent resection for BTC (30).
In our study, sarcopenia alone did not worsen the PFS
and OS in multivariate analysis. However, sarcopenia was
significantly associated with poor prognosis in the univariate
analysis. Concordant with our data, Yoon et al., who analyzed
the significance of sarcopenia on BTC, showed that a low skeletal
muscle index was not associated with improved survival in a
multivariate analysis (30). It is possible that BTC is more affected
by tumor specific factors rather than patient related factors such
as sarcopenia.
It remains controversial as to what the cut off values of
sarcopenia should be. Sarcopenia is related to several factors
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TABLE 3 | Univariate and multivariate analysis of overall survival.
Variables Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Sex (male vs. female) 1.24 1.00–1.55 0.050 1.41 1.09–1.84 0.010
Age (<67 vs. ≥67) 1.16 0.93–1.44 0.185
Pathology (WD/MD vs. PD) 1.53 1.15–2.03 0.003
ECOG <0.001 <0.001
ECOG 0 vs. ECOG 1 2.12 1.32–3.40 0.002 1.99 1.17–3.38 0.011
ECOG 0 vs. ECOG 2 2.98 1.85–4.78 <0.001 2.52 1.47–4.32 0.001
ECOG 0 vs. ECOG 3 6.84 3.94–11.88 <0.001 6.17 3.16–12.02 <0.001
ECOG 0 vs. ECOG 4 14.28 7.28–28.02 <0.001 5.98 1.92–18.61 0.002
CA 19-9 (per 100) 1.00 1.00–1.01 <0.001 1.00 1.00–1.004 0.032
CEA (per 20) 1.00 1.00–1.01 0.066
CRP (normal vs. elevated) 1.86 1.45–2.39 <0.001
Albumin (≥3.4 vs. <3.4) 1.97 1.54–2.51 <0.001
Protein (≥6.9 vs. <6.9) 1.43 1.15–1.77 0.001
Cholesterol (<139 vs. ≥139) 0.66 0.52–0.85 0.001
BUN (<23.0 vs. ≥23.0) 1.45 1.07–1.97 0.018
Bilirubin (<1.2 vs. ≥1.2) 0.99 0.80–1.23 0.920
NLR (<3.00 vs. ≥3.00) 1.94 1.55–2.43 <0.001
Sarcopenia (Yes vs. No) 0.77 0.62–0.96 0.020
VATI (low vs. high) 0.98 0.79–1.22 0.860
SATI (low vs. high) 0.86 0.69–1.06 0.156
BMI (<25 vs. ≥25) 0.81 0.63–1.03 0.085
Sarcopenia and NLR <0.001 0.004
Low NLR and no sarcopenia vs. either 1.69 1.28–2.22 <0.001 1.60 1.16–2.22 0.005
Low NLR and no sarcopenia vs. high NLR and sarcopenia 2.13 1.59–2.84 <0.001 1.80 1.25–2.59 0.002
HR, hazard ratio; CI, confidence interval; CBD, common bile duct; CCC, cholangiocarcinoma; GB, gallbladder; WD, well-differentiated; MD, moderately differentiated; PD, poorly
differentiated; ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CRP, C-reactive protein; BUN, blood urea nitrogen;
NLR, neutrophil lymphocyte ratio; VATI, visceral adipose tissue index; SATI, subcutaneous adipose tissue index.
FIGURE 5 | Progression free survival of patients with and without sarcopenia.
such as age, sex, ethnicity, and the region of the body used
for measurements. We adopted the cut off value from the JSH
guidelines which is based on Asian patients with liver disease
(23). As the amount of muscle wasting is different depending on
disease and ethnicity, further study would be helpful to clarify the
cut off value of sarcopenia in metastatic BTC.
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FIGURE 6 | Progression free survival of patients with high and low NLR.
FIGURE 7 | Progression free survival of patients depending on sarcopenia and NLR status.
Systemic inflammation is one of the crucial parameters that
can predict the cancer outcome in multiple cancers. Many
inflammatory markers, such as CRP, NLR, and PLR have been
associated with poor prognosis for various cancers (31–33).
Inflammation facilitates cancer progression through the
activation of phosphatidylinositol 3-kinase and the recruitment
of metalloproteinase-9, which promote cancer cell proliferation,
inhibit cell apoptosis (34), and promote angiogenesis and tumor
migration (35). Evidently, high NLR, which is associated with
inflammation, is linked to poor prognosis and poor response
to treatment, and has been demonstrated in various cancers
including melanoma (36), colorectal cancer (37, 38), intrahepatic
cholangiocarcinoma (39), prostate cancer (40), and pancreatic
cancer (41).
In BTC, the NLR cut off value of 3 is frequently used to
evaluate the inflammatory status. Several studies have compared
NLR values with OS in BTC. In these studies, the patients with
NLR > 3 had shorter OS than patients with NLR ≤ 3 (Median
OS; 21.6 vs. 12.0 months, p= 0.01). Patients with advanced stage
had more predictive NLR status than the surgical group (24, 25).
In our study, the OS was significantly different depending on
NLR status.
Notably, patients with inflammation accompanied by
sarcopenia were associated with poor prognosis. These patients
showed poor OS rates and more disease progression than those
without inflammation and sarcopenia. The relationship between
systemic inflammation and waste of muscle mass is gathering
increased attention over the recent years (19). There is a close
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TABLE 4 | Univariate and multivariate analysis of progression free survival.
Variables Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Sex (male vs. female) 1.24 1.00–1.542 0.047
Age (<67 vs. ≥67) 1.04 0.84–1.29 0.717
Pathology (WD/MD vs. PD) 1.67 1.26–2.21 <0.001 1.44 1.07–1.95 0.017
ECOG <0.001 <0.001
ECOG 0 vs. ECOG 1 1.68 1.09–2.59 0.018 1.48 0.92–2.39 0.110
ECOG 0 vs. ECOG 2 2.01 1.31–3.08 0.001 1.60 0.98–2.60 0.058
ECOG 0 vs. ECOG 3 4.49 2.69–7.49 <0.001 3.94 2.08–7.47 <0.001
ECOG 0 vs. ECOG 4 6.23 3.30–11.77 <0.001 2.02 0.67–6.03 0.210
CA 19-9 (per 100) 1.00 1.00–1.00 0.001 1.00 1.00–1.01 0.011
CEA (per 20) 1.00 0.99–1.01 0.220
CRP (normal vs. elevated) 1.71 1.34–2.18 <0.001
Albumin (≥3.4 vs. <3.4) 1.59 1.25–2.02 <0.001
Protein (≥6.9 vs. <6.9) 1.34 1.09–1.66 0.006
Cholesterol (<139 vs. ≥139) 0.71 0.55–0.90 0.005
BUN (<23.0 vs. ≥23.0) 1.23 0.90–1.67 0.191
Bilirubin (<1.2 vs. ≥1.2) 0.89 0.72–1.11 0.302
NLR (<3.00 vs. ≥3.00) 1.75 1.40–2.18 <0.001
Sarcopenia (Yes vs. No) 0.75 0.61–0.93 0.009
VATI (low vs. high) 0.92 0.74–1.13 0.416
SATI (low vs. high) 0.88 0.71–1.09 0.246
BMI (<25 vs. ≥25) 0.85 0.67–1.08 0.195
Sarcopenia and NLR <0.001 0.015
Low NLR and no sarcopenia vs. either 1.67 1.27–2.18 <0.001 1.49 1.09–2.04 0.014
Low NLR and no sarcopenia vs. high NLR and sarcopenia 2.00 1.50–2.65 <0.001 1.64 1.15–2.34 0.007
HR, hazard ratio; CI, confidence interval; CBD, common bile duct; CCC, cholangiocarcinoma; GB, gallbladder; WD, well-differentiated; MD, moderately differentiated; PD, poorly
differentiated; ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CRP, C-reactive protein; BUN, blood urea nitrogen;
NLR, neutrophil lymphocyte ratio; VATI, visceral adipose tissue index; SATI, subcutaneous adipose tissue index.
connection between inflammatory markers and the activation
of catabolic pathway (42). For instance, the tumor necrosis
factor (TNF) and interleukin 6 (IL-6), which are generated from
the tumors and the surrounding cells, can hasten both protein
degradation and also inhibit protein synthesis (43). Furthermore,
the tumor itself promotes inflammation, which tends to
facilitate tumor progression. The secretion of proinflammatory
myokines induces muscle degradation and exacerbates systemic
inflammation (12). Nevertheless, further studies are needed to
elucidate the mechanism between inflammation and sarcopenia.
The patients with sarcopenia in this study showed a high
level of inflammation related markers such as CRP and NLR,
suggesting that sarcopenia and inflammation are markers of
aggressive tumors (44). Similar results have been reported in head
and neck cancers. Cho et al. showed that sarcopenia accompanied
by systemic inflammation was significantly associated with poor
OS and PFS. In addition, the patients with sarcopenia showed
more frequent treatment interruptions due tomuscle wasting and
their inability to endure the treatment adverse effects (17).
In our study, sarcopenia accompanied by systemic
inflammation showed inferior OS and PFS. The poor treatment
outcome could be explained by the inability of these patients to
tolerate the treatment. Consistent with this notion, sarcopenia
did not lower the OS and PFS among the patients who received
GP chemotherapy which is the first line chemotherapy.
The adipose tissue composition of patients, VATI and SATI,
was not associated with long-term survival in our study.
However, there are reports that have demonstrated that high
visceral fat is associated with poor survival in cancer patients (45).
This discrepancy could be explained by the fact that there are
significantly less obese patients in Asia than in western countries.
In the other studies, overweight, or obese patients accounted for
over half of the total patient population (46, 47). In contrast, only
26.1% of our patients were overweight. Therefore, VATI could
affect the prognosis of Asian cancer patients; however, this study
does not have the power to determine whether or not it does as
the number of patients with high VATI included in this study
was insufficient.
There are some limitations in this study. First, the result
should be interpreted with caution due to its retrospective
nature. For example, though there was an association between
sarcopenia, systemic inflammation, and survival, we were unable
to define a causal relationship. Second, only Korean patients
were included in this study. The skeletal muscle mass varies
depending on the disease status and ethnicity of patients. For
this reason, diverse cut off values for sarcopenia were used.
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In this study, we adopted the sarcopenia definition created by
the Japan JSH. Yet, the optimal cut off value of sarcopenia
for Korean cancer patients is yet to be established. To define
the criteria for sarcopenia for the Korean population, especially
those with malignancy, further studies are necessary. Also,
for subgroup analysis, the number of patients received first
line GP chemotherapy were too small to show the statistical
power. To complement this limitation, study with larger number
of patients is needed. Despite these limitations, this is the
first study to demonstrate that sarcopenia accompanied by
systemic inflammation is associated with poor prognosis for
metastatic BTC.
In conclusion, BTC patients with distant metastasis that had
sarcopenia and systemic inflammation at diagnosis were
associated with poor OS. Exercise, nutritional support,
and pharmacological interventions that block muscle
atrophy signals or induce muscle hypertrophy could
enhance the survival of cancer patients with sarcopenia
and inflammation.
DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the
article/Supplementary Material.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Institutional review board of the Gangnam
Severance Hospital. Written informed consent for participation
was not required for this study in accordance with the national
legislation and the institutional requirements. Written informed
consent was not obtained from the individual(s) for the
publication of any potentially identifiable images or data included
in this article.
AUTHOR CONTRIBUTIONS
BL, HJ, and IL: study concept and design, manuscript
preparation, data acquisition, and data quality control. BL,
YC, HJ, and IL: data analysis and interpretation. YC and JK:
manuscript review. All authors: contributed to the article and
approved the submitted version.
FUNDING
This research was supported by a grant of the Korea
Health Technology R&D Project through the Korea Health
Industry Development Institute (KHIDI), funded by the
Ministry of Health & Welfare, Republic of Korea (grant
number: HI19C1330) and a National Research Foundation of
Korea Grant funded by the Korean Government (No. NRF-
2019R1A2C1085958).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fonc.
2020.01581/full#supplementary-material
Supplementary Figure 1 | Overall survival among patients who received GP
chemotherapy depending on sarcopenia.
Supplementary Figure 2 | Progression free survival among patients who
received GP chemotherapy depending on sarcopenia.
Supplementary Figure 3 | Overall survival among patients who received GP
chemotherapy depending on NLR.
Supplementary Figure 4 | Progression free survival among patients who
received GP chemotherapy depending on NLR.
Supplementary Table 1 | Univariate and multivariate analysis of OS using GP
chemotherapy.
Supplementary Table 2 | Univariate and multivariate analysis of PFS using GP
chemotherapy.
REFERENCES
1. Hanai T, Shiraki M, Nishimura K, Ohnishi S, Imai K, Suetsugu A, et al.
Sarcopenia impairs prognosis of patients with liver cirrhosis.Nutrition. (2015)
31:193–9. doi: 10.1016/j.nut.2014.07.005
2. Pereira RA, Cordeiro AC, Avesani CM, Carrero JJ, Lindholm B, Amparo
FC, et al. Sarcopenia in chronic kidney disease on conservative therapy:
prevalence and association with mortality. Nephrol Dial Transplant. (2015)
30:1718–25. doi: 10.1093/ndt/gfv133
3. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB,
Martin L, et al. Prevalence and clinical implications of sarcopenic
obesity in patients with solid tumours of the respiratory and
gastrointestinal tracts: a population-based study. Lancet Oncol. (2008)
9:629–35. doi: 10.1016/S1470-2045(08)70153-0
4. van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans
JN. Body composition and outcome in patients undergoing resection of
colorectal liver metastases. Br J Surg. (2012) 99:550–7. doi: 10.1002/bjs.
7823
5. Villasenor A, Ballard-Barbash R, Baumgartner K, Baumgartner R, Bernstein
L, McTiernan A, et al. Prevalence and prognostic effect of sarcopenia in
breast cancer survivors: the HEAL study. J Cancer Surviv. (2012) 6:398–
406. doi: 10.1007/s11764-012-0234-x
6. Okumura S, Kaido T, Hamaguchi Y, Fujimoto Y, Kobayashi A, Iida T,
et al. Impact of the preoperative quantity and quality of skeletal muscle on
outcomes after resection of extrahepatic biliary malignancies. Surgery. (2016)
159:821–33. doi: 10.1016/j.surg.2015.08.047
7. Otsuji H, Yokoyama Y, Ebata T, Igami T, Sugawara G, Mizuno T, et al.
Preoperative sarcopenia negatively impacts postoperative outcomes following
major hepatectomy with extrahepatic bile duct resection.World J Surg. (2015)
39:1494–500. doi: 10.1007/s00268-015-2988-6
8. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR,
et al. Prognostic effect of weight loss prior to chemotherapy in cancer
patients. Eastern Cooperative Oncology Group. Am J Med. (1980) 69:491–
7. doi: 10.1016/s0149-2918(05)80001-3
9. Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study G. Definition
of cancer cachexia: effect of weight loss, reduced food intake, and systemic
inflammation on functional status and prognosis. Am J Clin Nutr. (2006)
83:1345–50. doi: 10.1093/ajcn/83.6.1345
10. Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review
of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol.
(2005) 23:8500–11. doi: 10.1200/JCO.2005.01.8010
11. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia:
understanding the molecular basis. Nat Rev Cancer. (2014) 14:754–
62. doi: 10.1038/nrc3829
12. Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: a cross
talk between age-associated adipose tissue and skeletal muscle inflammation
as a main mechanism of the pathogenesis. Ageing Res Rev. (2017) 35:200–
21. doi: 10.1016/j.arr.2016.09.008
Frontiers in Oncology | www.frontiersin.org 10 September 2020 | Volume 10 | Article 1581
Lee et al. Sarcopenia in Biliary Tract Cancer
13. Fearon KC. Cancer cachexia: developing multimodal therapy
for a multidimensional problem. Eur J Cancer. (2008) 44:1124–
32. doi: 10.1016/j.ejca.2008.02.033
14. Bosaeus I. Nutritional support in multimodal therapy for cancer cachexia.
Support Care Cancer. (2008) 16:447–51. doi: 10.1007/s00520-007-0388-7
15. Davis JL, Langan RC, Panageas KS, Zheng J, Postow MA, Brady MS, et al.
Elevated blood neutrophil-to-lymphocyte ratio: a readily available biomarker
associated with death due to disease in high risk nonmetastatic melanoma.
Ann Surg Oncol. (2017) 24:1989–96. doi: 10.1245/s10434-017-5836-0
16. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, et al. High
blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in
malignant mesothelioma patients undergoing systemic therapy. Clin Cancer
Res. (2010) 16:5805–13. doi: 10.1158/1078-0432.CCR-10-2245
17. Cho Y, Kim JW, Keum KC, Lee CG, Jeung HC, Lee IJ. Prognostic
significance of sarcopenia with inflammation in patients with head and neck
cancer who underwent definitive chemoradiotherapy. Front Oncol. (2018)
8:457. doi: 10.3389/fonc.2018.00457
18. Go SI, Park MJ, Song HN, Kang MH, Park HJ, Jeon KN, et al. Sarcopenia
and inflammation are independent predictors of survival in male patients
newly diagnosed with small cell lung cancer. Support Care Cancer. (2016)
24:2075–84. doi: 10.1007/s00520-015-2997-x
19. Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan
ML, et al. Association of systemic inflammation and sarcopenia with survival
in nonmetastatic colorectal cancer: results from the C SCANS study. JAMA
Oncol. (2017) 3:e172319. doi: 10.1001/jamaoncol.2017.2319
20. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al.
Definition and classification of cancer cachexia: an international consensus.
Lancet Oncol. (2011) 12:489–95. doi: 10.1016/S1470-2045(10)70218-7
21. EvansWJ,Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia:
a new definition. Clin Nutr. (2008) 27:793–9. doi: 10.1016/j.clnu.2008.06.013
22. Kaasa S, Loge JH, Fayers P, Caraceni A, Strasser F, Hjermstad MJ, et al.
Symptom assessment in palliative care: a need for international collaboration.
J Clin Oncol. (2008) 26:3867–73. doi: 10.1200/JCO.2007.15.8881
23. Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S.
Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st
edition): recommendation from the working group for creation of sarcopenia
assessment criteria. Hepatol Res. (2016) 46:951–63. doi: 10.1111/hepr.12774
24. McNamara MG, Templeton AJ, Maganti M,Walter T, Horgan AM, McKeever
L, et al. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract
cancer. Eur J Cancer. (2014) 50:1581–9. doi: 10.1016/j.ejca.2014.02.015
25. Park HS, Park JS, Chun YJ, Roh YH,Moon J, ChonHJ, et al. Prognostic factors
and scoring model for survival in metastatic biliary tract cancer. Cancer Res
Treat. (2017) 49:1127–39. doi: 10.4143/crt.2016.538
26. Stene GB, Helbostad JL, Amundsen T, Sorhaug S, Hjelde H, Kaasa S,
et al. Changes in skeletal muscle mass during palliative chemotherapy
in patients with advanced lung cancer. Acta Oncol. (2015) 54:340–
8. doi: 10.3109/0284186X.2014.953259
27. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL,
et al. The influence of high body mass index on the prognosis of patients
with esophageal cancer after surgery as primary therapy. Cancer. (2010)
116:5619–27. doi: 10.1002/cncr.25745
28. Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima
Y, et al. Sarcopenia as a predictor of prognosis in patients following
hepatectomy for hepatocellular carcinoma. Br J Surg. (2013) 100:1523–
30. doi: 10.1002/bjs.9258
29. Jung HW, Kim JW, Kim JY, Kim SW, Yang HK, Lee JW, et al. Effect
of muscle mass on toxicity and survival in patients with colon cancer
undergoing adjuvant chemotherapy. Support Care Cancer. (2015) 23:687–
94. doi: 10.1007/s00520-014-2418-6
30. Yoon SB, Choi MH, Song M, Lee JH, Lee IS, Lee MA, et al.
Impact of preoperative body compositions on survival following resection
of biliary tract cancer. J Cachexia Sarcopenia Muscle. (2019) 10:794–
802. doi: 10.1002/jcsm.12431
31. Huang QT, Zhou L, Zeng WJ, Ma QQ, Wang W, Zhong M, et al. Prognostic
significance of neutrophil-to-lymphocyte ratio in ovarian cancer: a systematic
review and meta-analysis of observational studies. Cell Physiol Biochem.
(2017) 41:2411–8. doi: 10.1159/000475911
32. Zhou WJ, Wu J, Li XD, Wang Q, Ni XF, Jiang JT, et al. [Effect of
preoperative monocyte-lymphocyte ratio on prognosis of patients with
resectable esophagogastric junction cancer]. Zhonghua Zhong Liu Za Zhi.
(2017) 39:178–83. doi: 10.3760/cma.j.issn.0253-3766.2017.03.004
33. Cummings M, Merone L, Keeble C, Burland L, Grzelinski M, Sutton
K, et al. Preoperative neutrophil:lymphocyte and platelet:lymphocyte
ratios predict endometrial cancer survival. Br J Cancer. (2015) 113:311–
20. doi: 10.1038/bjc.2015.200
34. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al.
Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor
growth. Nat Med. (2010) 16:219–23. doi: 10.1038/nm.2084
35. Wilson TJ, Nannuru KC, Futakuchi M, Singh RK. Cathepsin G-
mediated enhanced TGF-beta signaling promotes angiogenesis
via upregulation of VEGF and MCP-1. Cancer Lett. (2010)
288:162–9. doi: 10.1016/j.canlet.2009.06.035
36. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al.
Elevated neutrophil and monocyte counts in peripheral blood are associated
with poor survival in patients with metastatic melanoma: a prognostic model.
Br J Cancer. (2005) 93:273–8. doi: 10.1038/sj.bjc.6602702
37. Grenader T, Nash S, Adams R, Kaplan R, Fisher D, Maughan T, et al. Derived
neutrophil lymphocyte ratio is predictive of survival from intermittent
therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN
study. Br J Cancer. (2016) 114:612–5. doi: 10.1038/bjc.2016.23
38. Sr W, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte
ratio as a prognostic factor in colorectal cancer. J Surg Oncol. (2005) 91:181–
4. doi: 10.1002/jso.20329
39. Lin GH, Liu YC, Li SH, Mao YZ, Wang J, Shuang ZY, et al. Elevated
neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in
patients with intrahepatic cholangiocarcinoma. Oncotarget. (2016) 7:50963–
71. doi: 10.18632/oncotarget.7680
40. Kawahara T, Yokomizo Y, Ito Y, Ito H, Ishiguro H, Teranishi J, et al.
Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis
in patients with metastatic prostate cancer. Bmc Cancer. (2016)
16:111. doi: 10.1186/s12885-016-2134-3
41. Hasegawa S, Eguchi H, Tomokuni A, Tomimaru Y, Asaoka T, Wada H,
et al. Pre-treatment neutrophil to lymphocyte ratio as a predictive marker
for pathological response to preoperative chemoradiotherapy in pancreatic
cancer. Oncol Lett. (2016) 11:1560–6. doi: 10.3892/ol.2015.4057
42. Kantola T, Klintrup K, Vayrynen JP, Vornanen J, Bloigu R, Karhu T, et al.
Stage-dependent alterations of the serum cytokine pattern in colorectal
carcinoma. Br J Cancer. (2012) 107:1729–36. doi: 10.1038/bjc.2012.456
43. Baracos VE. Regulation of skeletal-muscle-protein turnover
in cancer-associated cachexia. Nutrition. (2000) 16:1015–
8. doi: 10.1016/s0899-9007(00)00407-x
44. Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT,
et al. Muscle wasting in cancer cachexia: clinical implications,
diagnosis, and emerging treatment strategies. Annu Rev Med. (2011)
62:265–79. doi: 10.1146/annurev-med-061509-131248
45. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role
of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. (2009)
18:2569–78. doi: 10.1158/1055-9965.EPI-09-0372
46. Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette
P, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-
limiting toxicities in renal cancer patients. Br J Cancer. (2013) 108:1034–
41. doi: 10.1038/bjc.2013.58
47. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body
mass index and sarcopenia associated with dose-limiting toxicity of
sorafenib in patients with renal cell carcinoma. Ann Oncol. (2010) 21:1594–
8. doi: 10.1093/annonc/mdp605
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Lee, Cho, Kim, Jeung and Lee. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Oncology | www.frontiersin.org 11 September 2020 | Volume 10 | Article 1581
